EconPapers    
Economics at your fingertips  
 

Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: Evidence from a randomised controlled trial in Nepal

Emilie Alirol, Sanjib Kumar Sharma, Anup Ghimire, Antoine Poncet, Christophe Combescure, Chabilal Thapa, Vijaya Prasad Paudel, Kalidas Adhikary, Walter Robert Taylor, David Warrell, Ulrich Kuch and François Chappuis

PLOS Neglected Tropical Diseases, 2017, vol. 11, issue 5, 1-15

Abstract: Background: Currently, there is inadequate evidence on which to base clinical management of neurotoxic snakebite envenoming, especially in the choice of initial antivenom dosage. This randomised controlled trial compared the effectiveness and safety of high versus low initial antivenom dosage in victims of neurotoxic envenoming. Methodology/ Principal findings: This was a balanced, randomised, double-blind trial that was conducted in three health care centers located in the Terai plains of Nepal. Participants received either low (two vials) or high (10 vials) initial dosage of Indian polyvalent antivenom. The primary composite outcome consisted of death, the need for assisted ventilation and worsening/recurrence of neurotoxicity. Hourly evaluations followed antivenom treatment. Between April 2011 and October 2012, 157 snakebite victims were enrolled, of which 154 were analysed (76 in the low and 78 in the high initial dose group). Sixty-seven (43·5%) participants met the primary outcome definition. The proportions were similar in the low (37 or 48.7%) vs. high (30 or 38.5%) initial dose group (difference = 10·2%, 95%CI [-6·7 to 27·1], p = 0·264). The mean number of vials used was similar between treatment groups. Overall, patients bitten by kraits did worse than those bitten by cobras. The occurrence of treatment-related adverse events did not differ among treatment groups. A total of 19 serious adverse events occurred, including seven attributed to antivenom. Conclusions: This first robust trial investigating antivenom dosage for neurotoxic snakebite envenoming shows that the antivenom currently used in Nepal performs poorly. Although the high initial dose regimen is not more effective than the low initial dose, it offers the practical advantage of being a single dose, while not incurring higher consumption or enhanced risk of adverse reaction. The development of new and more effective antivenoms that better target the species responsible for bites in the region will help improve future patients’ outcomes. Trial registration: The study was registered on clinicaltrials.gov (NCT01284855) (GJ 5/1) Author summary: Snakebite is an important medical problem in tropical regions, including in Nepal where tens of thousands of people are bitten every year. Snakebite can result in life-threatening envenoming and correct identification of the biting species is crucial for doctors to choose appropriate treatment and anticipate complications. This paper compares two different doses of antivenom for the treatment of neurotoxic snakebite envenoming. Out of 157 snakebite victims presenting to one of the study centers, 78 received a low initial dose and 79 received a high initial dose. The proportion of patients who either died, needed breathing support or additional doses of antivenom were the same in the two groups. Overall, patients bitten by kraits did worse than those bitten by cobras. The occurrence of adverse reactions was comparable among those received low or high initial dose respectively. This study is the first to use a rigorous and robust method for comparing doses of antivenom in snakebite victims in South Asia. Although the high initial dose was not more effective than the low initial dose, it offers the practical advantage of being simpler to administer and was as safe as the low initial dose. The development of new and more effective antivenoms that better target the species responsible for bites in the region will help improve future patients’ outcomes.

Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005612 (text/html)
https://journals.plos.org/plosntds/article/file?id ... 05612&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pntd00:0005612

DOI: 10.1371/journal.pntd.0005612

Access Statistics for this article

More articles in PLOS Neglected Tropical Diseases from Public Library of Science
Bibliographic data for series maintained by plosntds ().

 
Page updated 2025-03-22
Handle: RePEc:plo:pntd00:0005612